Zharmakhanova Gulmira, Kononets Victoria, Balmagambetova Saule, Syrlybayeva Lyazzat, Nurbaulina Eleonora, Zhussupova Zhanna, Sakhanova Svetlana, Ayaganov Dinmukhamed, Kim Svetlana, Zhumalina Akmaral
Department of Natural Sciences, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Department of Oncology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan.
Front Genet. 2024 Jan 12;14:1278750. doi: 10.3389/fgene.2023.1278750. eCollection 2023.
Data on the prevalence of most inborn errors of metabolism are still unavailable in Kazakhstan. The study aims to perform selective screening for hereditary metabolic diseases among patients aged from 1 day to 18 years in western Kazakhstan using the LC-MS/MS method, with establishing the reference values for the content of amino acids, acylcarnitines, and succinylacetone in blood samples of healthy children. Tasks: 1. To assess the burden of metabolic disorders detected by LC-MS/MS in western Kazakhstan by examination of children at clinical risk in pediatric clinics throughout the region; https://www.frontiersin.org/register?returnUrl=https://loop.frontiersin.org 2. To set the reference values of metabolites in the child population; 3. To analyze the age distribution, prevalence, and age of onset for each identified IEM, further comparing the obtained findings with those from previously published reports in other populations.
To set the reference values of 51 metabolites in the child population, 750 healthy children will be included. The selective screening will be performed among 1,500 patients aged 1 day to 18 years with suspected hereditary metabolic disorders.
The results of selective screening will be interpreted by comparison with the reference values established. Diagnosis will be based on clinical signs, blood levels of amino acids, acylcarnitines, succinylacetone, and urine levels of organic acids and tests for gene mutations. An assessment of 37 inborn errors of metabolism frequencies in high-risk children will be performed. The research will further develop the national as selective as expanded newborn screening programs. The study was registered in clinicaltrials. gov (https://www.
gov/study/NCT05910151) on 16 June 2023.
哈萨克斯坦仍没有大多数先天性代谢缺陷病的患病率数据。本研究旨在使用液相色谱-串联质谱法(LC-MS/MS)对哈萨克斯坦西部1天至18岁的患者进行遗传性代谢疾病的选择性筛查,并建立健康儿童血样中氨基酸、酰基肉碱和琥珀酰丙酮含量的参考值。任务:1. 通过对该地区儿科诊所具有临床风险的儿童进行检查,评估LC-MS/MS在哈萨克斯坦西部检测到的代谢紊乱负担;https://www.frontiersin.org/register?returnUrl=https://loop.frontiersin.org 2. 设定儿童群体中代谢物的参考值;3. 分析每种已识别的先天性代谢缺陷病(IEM)的年龄分布、患病率和发病年龄,并将所得结果与其他人群先前发表的报告结果进行进一步比较。
为设定儿童群体中51种代谢物的参考值,将纳入750名健康儿童。将对1500名年龄在1天至18岁、疑似患有遗传性代谢疾病的患者进行选择性筛查。
将通过与所建立的参考值进行比较来解释选择性筛查的结果。诊断将基于临床体征、血液中氨基酸、酰基肉碱、琥珀酰丙酮的水平、尿液中有机酸的水平以及基因突变检测。将对高危儿童中37种先天性代谢缺陷病的发生频率进行评估。该研究将进一步发展全国性的、如同扩大新生儿筛查项目一样具有选择性的项目。该研究于2023年6月16日在ClinicalTrials.gov(https://www.
ClinicalTrials.gov/study/NCT05910151)注册。